Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed |
|---|---|---|
|
Kazia Therapeutics Ltd
13G/A
Amendment 4
KZIA · 48669G105
|
5.4% |
10/2/2026
Event 9/25/2026
|
|
Azitra, Inc.
13G
AZTR · 05479L203
|
9.6% |
6/25/2026
Event 6/24/2026
|
|
OKYO Pharma Ltd
13G/A
Amendment 3
OKYO · G6724L116
|
1.2% |
2/12/2026
Event 12/31/2025
|
|
Kazia Therapeutics Ltd
13G/A
Amendment 3
KZIA · 48669G105
|
0% |
2/12/2026
Event 12/31/2025
|
|
OKYO Pharma Ltd
13G/A
Amendment 2
OKYO · G6724L116
|
6.3% |
11/14/2025
Event 9/30/2025
|
|
Kazia Therapeutics Ltd
13G/A
Amendment 2
KZIA · 48669G105
|
9.9% |
11/14/2025
Event 9/30/2025
|
|
Femasys Inc
13G/A
Amendment 1
FEMY · 31447E105
|
9.9% |
11/14/2025
Event 9/30/2025
|
|
OKYO Pharma Ltd
13G/A
Amendment 1
OKYO · G6724L116
|
7.3% |
8/5/2025
Event 6/30/2025
|
|
Kazia Therapeutics Ltd
13G/A
Amendment 1
KZIA · 48669G105
|
8.4% |
8/5/2025
Event 6/30/2025
|
|
Kazia Therapeutics Ltd
13G
KZIA · 48669G105
|
5.9% |
6/13/2025
Event 6/11/2025
|
|
OKYO Pharma Ltd
13G
OKYO · G6724L116
|
5.9% |
3/18/2025
Event 3/12/2025
|
|
AEON Biopharma, Inc.
13G
AEON · 00791X209
|
9.7% |
3/3/2025
Event 2/26/2025
|
|
Femasys Inc
13G
FEMY · 31447E105
|
5.4% |
2/26/2025
Event 2/18/2025
|